• ChemFaces is a professional high-purity natural products manufacturer.
  • Product Intended Use
  • 1. Reference standards
  • 2. Pharmacological research
  • 3. Inhibitors
  • Home
  • Natural Products
  • Bioactive
  • Screening Libraries
  • Hot Products
  • Plant Catalog
  • Customer Support
  • Product Use Citation
  • About Us
  • Contact Us
  • Natural Products
    Decursin
    Information
    CAS No. 5928-25-6 Price $228 / 20mg
    Catalog No.CFN98509Purity>=98%
    Molecular Weight328.36Type of CompoundCoumarins
    FormulaC19H20O5Physical DescriptionPowder
    Download Manual    COA    MSDSSimilar structuralComparison (Web)
    How to Order
    Orders via your E-mail:

    1. Product number / Name / CAS No.
    2. Delivery address
    3. Ordering/billing address
    4. Contact information
    Sent to Email: info@chemfaces.com
    Contact Us
    Order & Inquiry & Tech Support

    Tel: (0086)-27-84237683
    Fax: (0086)-27-84254680
    E-mail: manager@chemfaces.com
    Address: No. 83, CheCheng Rd., WETDZ, Wuhan, Hubei 430056, PRC
    Delivery time
    Delivery & Payment method

    1. Usually delivery time: Next day delivery by 9:00 a.m. Order now

    2. We accept: Wire transfer & Credit card & Paypal & Western Union
    * Packaging according to customer requirements(5mg, 10mg, 20mg and more). We shipped via FedEx, DHL, UPS, EMS and others courier.
    Our products had been exported to the following research institutions and universities, And still growing.
  • Universidade Federal de Pernambu... (Brazil)
  • Korea Institute of Oriental Medi... (Korea)
  • Lund University (Sweden)
  • VIB Department of Plant Systems ... (Belgium)
  • University of Melbourne (Australia)
  • Institute of Bioorganic Chemistr... (Poland)
  • Complutense University of Madrid (Spain)
  • Monash University Sunway Campus (Malaysia)
  • Kyushu University (Japan)
  • MTT Agrifood Research Finland (Finland)
  • University of Limpopo (South Africa)
  • More...
  • Package
    Featured Products
    Polygalaxanthone III

    Catalog No: CFN90208
    CAS No: 162857-78-5
    Price: $138/20mg
    Ganoderenic acid D

    Catalog No: CFN90300
    CAS No: 100665-43-8
    Price: $476/10mg
    Afzelin

    Catalog No: CFN98757
    CAS No: 482-39-3
    Price: $288/20mg
    Nodakenetin

    Catalog No: CFN98788
    CAS No: 495-32-9
    Price: $268/10mg
    Quercetin-3-gentiobioside

    Catalog No: CFN93585
    CAS No: 7431-83-6
    Price: $298/10mg
    Biological Activity
    Description: Decursin has antiepileptic, hepatoprotective, anti-cancer, anti-inflammatory, and anti-amnesic activities, it is a novel candidate for inhibition of VEGF-induced angiogenesis. Decursin inhibited the TGF-β1 induced NOX activation and Smad signaling, it inhibited the PKCα, MAPK and NF-κB pathways. Decursin is also a novel inhibitor of NF-kappaB activation in signaling induced by TLR ligands and cytokines.
    Targets: NADPH-oxidase | TGF-β/Smad | AChR | NF-kB | MMP(e.g.TIMP) | p38MAPK | PKC | p53 | P450 (e.g. CYP17) | VEGFR | JNK | LTR | IL Receptor | TNF-α
    In vitro:
    Int J Oncol. 2014 May;44(5):1607-13.
    Decursin prevents TPA-induced invasion through suppression of PKCα/p38/NF-κB-dependent MMP-9 expression in MCF-7 human breast carcinoma cells.[Pubmed: 24604087]
    Decursin, a coumarin compound, was first isolated from the roots of Angelica gigas almost four decades ago. It was found to exhibit cytotoxicity against various human cancer cells and to possess anti-amnesic activity in vivo through the inhibition of AChE activity. However, the effect of Decursin on breast cancer invasion is unknown. Matrix metalloproteinase-9 (MMP-9) is known to be an important factor for cancer cell invasion.
    METHODS AND RESULTS:
    Therefore, in this study, we investigated the inhibitory effect of Decursin on 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced MMP-9 expression and cell invasion, as well as the molecular mechanisms involved in MCF-7 cells. Our results showed that Decursin inhibits TPA-induced MMP-9 expression and cell invasion through the suppression of NF-κB. Furthermore, Decursin repressed the TPA-induced phosphorylation of p38 MAPK and inhibited TPA-induced translocation of PKCα from the cytosol to the membrane, but did not affect the translocation of PKCδ.
    CONCLUSIONS:
    These results indicate that Decursin-mediated inhibition of TPA-induced MMP-9 expression and cell invasion involves the suppression of the PKCα, MAPK and NF-κB pathways in MCF-7 cells. Thus, Decursin may have potential value in restricting breast cancer metastasis.
    Carcinogenesis. 2009 Apr;30(4):655-61.
    Decursin and decursinol angelate inhibit VEGF-induced angiogenesis via suppression of the VEGFR-2-signaling pathway.[Pubmed: 19228635 ]
    Inhibition of angiogenesis is an attractive approach for the treatment of angiogenic diseases, such as cancer. Vascular endothelial growth factor (VEGF) is one of the most important activators of angiogenesis and interacts with the high-affinity tyrosine kinase receptors, VEGFR-1 and VEGFR-2. The pyranocoumarin compounds Decursin and Decursinol angelate isolated from the herb, Angelica gigas, are known to possess potent anti-inflammatory activities. However, little is known about their antiangiogenic activity or their underlying mechanisms.
    METHODS AND RESULTS:
    Here, we show the antiangiogenic effects of Decursin and Decursinol angelate using in vitro assays and in vivo animal experiments. Decursin and Decursinol angelate inhibited VEGF-induced angiogenic processes in vitro, including proliferation, migration and tube formation of human umbilical vein endothelial cells. Decursin and Decursinol angelate significantly suppressed neovessel formation in chick chorioallantoic membrane and tumor growth in a mouse model. The microvessel density in tumors treated with Decursin for 14 days was significantly decreased compared with a vehicle control group. Decursin and Decursinol angelate inhibited VEGF-induced phosphorylation of VEGFR-2, extracellular signal-regulated kinases and c-Jun N-terminal kinase mitogen-activated protein kinases.
    CONCLUSIONS:
    Taken together, these results demonstrate that Decursin and Decursinol angelate are novel candidates for inhibition of VEGF-induced angiogenesis.
    In vivo:
    Life Sci. 2014 Jul 17;108(2):94-103.
    Decursin attenuates hepatic fibrogenesis through interrupting TGF-beta-mediated NAD(P)H oxidase activation and Smad signaling in vivo and in vitro.[Pubmed: 24880074]
    We studied that a potent antifibrotic effect of Decursin on in vivo liver damage model and the mechanism in inhibiting which transforming growth factor (TGF)-β1-induced human hepatic stellate cells (HSCs) activation.
    METHODS AND RESULTS:
    Liver injury was induced in vivo by intraperitoneal injection of carbon tetrachloride (CCl4) with or without Decursin for 4weeks in mice. Human hepatic stellate cell line, an immortalized human HSC line, was used in in vitro assay system. The effects of Decursin on HSC activation were measured by analyzing the expression of α-smooth muscle actin (α-SMA) and collagen I in liver tissue and human HSCs. Decursin treatment significantly reduced the ratio of liver/body weight, α-SMA activation, and type I collagen overexpression in CCl4 treated mice liver. The elevated serum levels, including ALT, AST, and ALP, were also decreased by Decursin treatment. Treatment of Decursin markedly proved the generation of reactive oxygen species, NAD(P)H oxidase (NOX) protein (1, 2, and 4) upregulation, NOX activity, and superoxide anion production in HSCs by TGF-β1. It also significantly reduced TGF-β1-induced Smad 2/3 phosphorylation, nuclear translocation of Smad 4, and association of Smad 2/3-Smad 4 complex. Consistent with in vitro results, Decursin treatment effectively blocked the levels of NOX protein, and Smad 2/3 phosphorylation in injured mice liver.
    CONCLUSIONS:
    Decursin blocked CCl4-induced liver fibrosis and inhibited TGF-β1-mediated HSC activation in vitro. These data demonstrated that Decursin exhibited hepatoprotective effects on experimental fibrosis, potentially by inhibiting the TGF-β1 induced NOX activation and Smad signaling.
    Neuroreport. 2014 Nov 12;25(16):1243-9.
    Decursin attenuates kainic acid-induced seizures in mice.[Pubmed: 25171200]
    Epilepsy is a neurological disorder with recurrent unprovoked seizures as the main symptom. Of the coumarin derivatives in Angelica gigas, Decursin, a major coumarin component, was reported to exhibit significant protective activity against glutamate-induced neurotoxicity when added to primary cultures of rat cortical cells. This study served to investigate the effects of Decursin on a kainic acid (KA)-induced status epilepticus model.
    METHODS AND RESULTS:
    Thirty minutes after intraperitoneal injections of Decursin (20 mg/kg) in male 7-week-old C57BL/6 mice, the animals were treated with KA (30 mg/kg, intraperitoneally) and then examined for behavioral seizure score, electroencephalogram, seizure-related expressed protein levels, neuronal cell loss, neurodegeneration, and astrogliosis. KA injections significantly enhanced neurodegenerative conditions but treatment with Decursin 30 min before KA injection reduced the detrimental effects of KA in mice. The Decursin-treated KA-injected group showed significantly decreased behavioral seizure activity and remarkably attenuated intense and high-frequency seizure discharges in the parietal cortex for 2 h compared with the group treated only with KA. Furthermore, in-vivo results indicated that Decursin strongly inhibits selective neuronal death, astrogliosis, and oxidative stress induced by KA administration.
    CONCLUSIONS:
    Therefore Decursin is able to attenuate KA-induced seizures and could have potential as an antiepileptic drug.
    Decursin Description
    Source: The roots of Peucedanum ostruthium
    Solvent: Chloroform, Dichloromethane, Ethyl Acetate, DMSO, Acetone, etc.
    Storage: Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 24 months(2-8C).

    Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.

    Need more advice on solubility, usage and handling? Please email to: service@chemfaces.com

    After receiving: The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.
    Recent ChemFaces New Products and Compounds
    Shancigusin I

    Catalog No: CFN95061
    CAS No: 1435488-35-9
    Price: $388/5mg
    Betmidin

    Catalog No: CFN95047
    CAS No: 35589-22-1
    Price: $413/5mg
    Juglanin

    Catalog No: CFN96238
    CAS No: 5041-67-8
    Price: $368/5mg
    Zederone

    Catalog No: CFN92616
    CAS No: 7727-79-9
    Price: $278/20mg
    Selaginellin

    Catalog No: CFN95030
    CAS No: 941269-84-7
    Price: $368/5mg
    Quercetin-3-O-glucuronide

    Catalog No: CFN92172
    CAS No: 22688-79-5
    Price: $318/10mg
    9-O-Acetyl-fargesol

    Catalog No: CFN95031
    CAS No: 449172-61-6
    Price: $413/5mg
    Quercetin 3-O-beta-(6''-p-coumaroy...

    Catalog No: CFN95088
    CAS No: 143061-65-8
    Price: $338/5mg
    Recently, ChemFaces products have been cited in many studies from excellent and top scientific journals

    Cell. 2018 Jan 11;172(1-2):249-261.e12.
    doi: 10.1016/j.cell.2017.12.019.

    PMID: 29328914

    Mol Cell. 2017 Nov 16;68(4):673-685.e6.
    doi: 10.1016/j.molcel.2017.10.022.

    PMID: 29149595

    Scientific Reports 2017 Dec 11;7(1):17332.
    doi: 10.1038/s41598-017-17427-6.

    PMID: 29230013

    Molecules. 2017 Oct 27;22(11). pii: E1829.
    doi: 10.3390/molecules22111829.

    PMID: 29077044

    J Cell Biochem. 2018 Feb;119(2):2231-2239.
    doi: 10.1002/jcb.26385.

    PMID: 28857247

    Phytomedicine. 2018 Feb 1;40:37-47.
    doi: 10.1016/j.phymed.2017.12.030.

    PMID: 29496173
    Calculate Dilution Ratios(Only for Reference)
    1 mg 5 mg 10 mg 20 mg 25 mg
    1 mM 3.0454 mL 15.2272 mL 30.4544 mL 60.9088 mL 76.1359 mL
    5 mM 0.6091 mL 3.0454 mL 6.0909 mL 12.1818 mL 15.2272 mL
    10 mM 0.3045 mL 1.5227 mL 3.0454 mL 6.0909 mL 7.6136 mL
    50 mM 0.0609 mL 0.3045 mL 0.6091 mL 1.2182 mL 1.5227 mL
    100 mM 0.0305 mL 0.1523 mL 0.3045 mL 0.6091 mL 0.7614 mL
    * Note: If you are in the process of experiment, it's need to make the dilution ratios of the samples. The dilution data of the sheet for your reference. Normally, it's can get a better solubility within lower of Concentrations.
    Protocol
    Kinase Assay:
    Phytother Res. 2014 Feb;28(2):238-44.
    Decursin exerts anti-cancer activity in MDA-MB-231 breast cancer cells via inhibition of the Pin1 activity and enhancement of the Pin1/p53 association.[Pubmed: 23580332]
    The peptidyl-prolyl cis/trans isomerase Pin1 is overexpressed in a wide variety of cancer cells and thus considered as an important target molecule for cancer therapy.
    METHODS AND RESULTS:
    This study demonstrates that Decursin, a bioactive compound from Angelica gigas, exert the anti-cancer effect against breast cancer cells via regulation of Pin1 and its related signaling molecules. We observed that Decursin induced G1 arrest with decrease in cyclin D1 level in Pin1-expressing breast cancer cells MDA-MB-231, but not Pin1-non-expressing breast cancer cells MDA-MB-157. In addition, Decursin significantly reduced protein expression and enzymatic activity of Pin1 in MDA-MB-231 cells. Further, we found that Decursin treatment enhanced the p53 expression level and failed to down-regulate Pin1 in the cells transfected with p53 siRNA, indicating the importance of p53 in the Decursin-mediated Pin1 inhibition in MDA-MB-231 cells. Decursin stimulated association between Pin1 to p53. Moreover, Decursin facilitated p53 transcription in MDA-MB-231 cells.
    CONCLUSIONS:
    Overall, our current study suggests the potential of Decursin as an attractive cancer therapeutic agent for breast cancer by targeting Pin1 protein.
    Food Chem Toxicol. 2014 Aug;70:94-9.
    Potential of decursin to inhibit the human cytochrome P450 2J2 isoform.[Pubmed: 24788058]
    CYP2J2 enzyme is highly expressed in human tumors and carcinoma cell lines, and epoxyeicosatrienoic acids, CYP2J2-mediated metabolites, have been implicated in the pathologic development of human cancers.
    METHODS AND RESULTS:
    To identify a CYP2J2 inhibitor, 50 natural products obtained from plants were screened using astemizole as a CYP2J2 probe substrate in human liver microsomes. Of these, Decursin noncompetitively inhibited CYP2J2-mediated astemizole O-demethylation and terfenadine hydroxylation activities with Ki values of 8.34 and 15.8μM, respectively. It also showed cytotoxic effects against human hepatoma HepG2 cells in a dose-dependent manner while it did not show cytotoxicity against mouse hepatocytes.
    CONCLUSIONS:
    The present data suggest that Decursin is a potential candidate for further evaluation for its CYP2J2 targeting anti-cancer activities. Studies are currently underway to test Decursin as a potential therapeutic agent for cancer.
    Cell Research:
    Mol Pharmacol. 2006 Jun;69(6):1783-90.
    Decursin inhibits induction of inflammatory mediators by blocking nuclear factor-kappaB activation in macrophages.[Pubmed: 16510559 ]
    In the course of screening inhibitors of matrix metalloproteinase (MMP)-9 induction in macrophages, we isolated Decursin, a coumarin compound, from the roots of Angelicae gigas. As a marker for the screening and isolation, we tested expression of MMP-9 in RAW264.7 cells and THP-1 cells after treatment with bacterial lipopolysaccharide (LPS), the TLR-4 ligand.
    METHODS AND RESULTS:
    Decursin suppressed MMP-9 expression in cells stimulated by LPS in a dose-dependent manner at concentrations below 60 microM with no sign of cytotoxicity. The suppressive effect of Decursin was observed not only in cells stimulated with ligands for TLR4, TLR2, TLR3, and TLR9 but also in cells stimulated with interleukin (IL)-1beta, and tumor necrosis factor (TNF)-alpha, indicating that the molecular target of Decursin is common signaling molecules induced by these stimulants. In addition to the suppression of MMP-9 expression, Decursin blocked nitric oxide production and cytokine (IL-8, MCP-1, IL-1beta, and TNF-alpha) secretion induced by LPS. To find out the molecular mechanism responsible for the suppressive effect of Decursin, we analyzed signaling molecules involved in the TLR-mediated activation of MMP-9 and cytokines. Decursin blocked phosphorylation of IkappaB and nuclear translocation of NF-kappaB in THP-1 cells activated with LPS. Furthermore, expression of a luciferase reporter gene under the promoter containing NF-kappaB binding sites was blocked by Decursin.
    CONCLUSIONS:
    These data indicate that Decursin is a novel inhibitor of NF-kappaB activation in signaling induced by TLR ligands and cytokines.